human chemerin quantikine elisa kit  (R&D Systems)

Journal: Frontiers in Medicine

Article Title: Evaluation of chemerin levels in the pathogenesis of psoriasis

doi: 10.3389/fmed.2026.1748469

Figure Lengend Snippet: Comparison between chemerin level in healthy (CTRL) patient’s serum, and psoriatic patient’s serum [pg/ml]. a- p < 0.05.

Article Snippet: Serum chemerin levels (pg/mL) were measured using the Human Chemerin Quantikine ELISA (R&D Systems) following the manufacturer’s instructions in the Department of Neurodegeneration Diagnostics.

Techniques: Comparison

Journal: Frontiers in Medicine

Article Title: Evaluation of chemerin levels in the pathogenesis of psoriasis

doi: 10.3389/fmed.2026.1748469

Figure Lengend Snippet: The scatterplot shows a correlation between chemerin and the level of platelet count (PLT) in the serum of patients with psoriasis.

Article Snippet: Serum chemerin levels (pg/mL) were measured using the Human Chemerin Quantikine ELISA (R&D Systems) following the manufacturer’s instructions in the Department of Neurodegeneration Diagnostics.

Techniques:

Journal: CNS Neuroscience & Therapeutics

Article Title: CircMAN1A2 Levels Determine GBM Susceptibility to TMZ in a Pathway Involving TEP1‐ and KEAP1 ‐Mediated NRF2 Degradation Leading to Ferroptosis

doi: 10.1111/cns.70489

Figure Lengend Snippet: NRF2 transcriptionally upregulates ANXA1 expression in GSC to promote TAM recruitment and M2 polarization. (a) The umap plot of GSE131928 single cell sequencing. (b) Venn diagram of the intersection of differentially transcribed genes and genes differentially upregulated for protein activity. (c–e) Correlation analysis of NFE2L2 with CD44, TNFRSF1A, ANXA1 in glioma tissues (data from GEPIA2 database). (f) The qPCR results showed the level of ANXA1 mRNA expression in GSC that interfered with NFE2L2. (g) ChIP assay showing the level of ANXA1 transcriptional promoter enrichment after interference with NFE2L2. (h) ELISA assay showing the expression level of ANXA1 protein in cell supernatants after interference with NFE2L2. (i) Western blot assay showing the expression level of ANXA1 protein in cells after interference with NFE2L2. (j) Schematic representation of the DNA binding motif of NFE2L2. (k) Schematic representation of the ANXA1 promoter mutation. (l) Dual luciferase reporter gene assay interferes with ANXA1 transcriptional activity after NFE2L2.

Article Snippet: Chemerin and ANXA1 concentration in healthy donors' and glioma patients' serum or in the 24 h supernatant of cultured GBM cells were measured by commercial Human Chemerin ELISA Kits (DCHM00, R&D Systems) and Human ANXA1 Quantikine ELISA Kit (DTA00D, R&D Systems), respectively.

Techniques: Expressing, Sequencing, Activity Assay, Enzyme-linked Immunosorbent Assay, Western Blot, Binding Assay, Mutagenesis, Luciferase, Reporter Gene Assay